Clinical Trial Search

Primary: Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy — 22; 20; 25; 36 participants — p=0.066

Primary: Number of Ventilator-free Days — 95.9; 93.6 days — p=0.08

Primary: Attendance at First Depression Treatment Appointment — 5; 6 participants

Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants

Primary: Mean Change From Baseline in Forced Vital Capacity (FVC) — 0.1786 Liters — p=0.026

Primary: Maximum Tolerated Dose of MGd (Phase I) — 0; 0; 1 units on a scale

Primary: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores; — 40; 88 percentage of pts — p=0.009

Primary: Change in HbA1c From Baseline to Week 12 — -0.22; -0.79; -0.76; -0.70 Percent — p=<0.001

Primary: Number of Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) as Assessed by CTCAE v. 3.0 Criteria Within the First 90 Days From…

Primary: Number of Participants With Peripheral Edema — 5; 9; 2; 0 Participants

Primary: Change in Flow-mediated Dilation of the Brachial Artery — -1.93; -1.06 absolute percentage — p=0.44

Primary: Knowledge of Breast Cancer Risk Factors — 48.9; 56.4 units on a scale

Primary: Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation — 31 participants

Primary: Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines — 18 percent agreement

Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37